ASCO GU 2019 Press Releases

MDxHealth Announces Presentation of Positive Data for SelectMDx and ConfirmMDx in Prostate Cancer Diagnosis

San Francisco, CA USA (UroToday.com) --MDxHealth SA announced that positive data and observations from multiple studies and patient registries demonstrating the value of SelectMDx and ConfirmMDx for Prostate Cancer diagnosis, were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), taking place in San Francisco, California from February 14-16, 2019.

Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer

San Francisco, CA USA (UroToday.com) -- Pfizer Inc. and Astellas Pharma Inc., President and CEO: Kenji Yasukawa, Ph.D., Astellas, announced results from the Phase 3 ARCHES trial in men with metastatic hormone-sensitive prostate cancer (mHSPC). Prostate cancer is considered metastatic once the cancer has spread outside of the prostate gland to other parts of the body.¹ Men are considered hormone (or castration) sensitive if their disease still responds to medical or surgical treatment to lower testosterone levels.²

Phase II Trial Shows Novel, Radiolabeled PSMA-Targeted Treatment Provides High Response Rates in Men with Metastatic Prostate Cancer

San Francisco, CA USA (UroToday.com) -- A single-arm, phase II trial in men with PSMA-positive metastatic, castration-resistant prostate cancer (mCRPC) that progressed despite standard therapies, found that in the majority of men, the cancers were responsive to treatment with a novel, targeted radiation therapy called Lutetium-177 PSMA-617 (LuPSMA). This is the first prospective study of LuPSMA, part of a potential new class of treatments for men with metastatic prostate cancer. According to the researchers, men receiving the medication lived a median of 13.3 months after treatment, longer than the average 9-month survival time for men with this stage of the disease. These findings will be presented at the upcoming 2019 Genitourinary Cancers Symposium in San Francisco, California.

African-American Men with Advanced Prostate Cancer Live Longer Compared With White Men When Treated with Newer Hormone Therapies

San Francisco, CA USA (UroToday.com) -- A large, retrospective study analyzing five years of data from the Veterans Health Administration (VHA) found that African-American men with metastatic castration-resistant prostate cancer (mCRPC) who were treated with newer prostate cancer drugs abiraterone acetate (Zytiga) or enzalutamide (Xtandi) – and who had not received prior chemotherapy – lived 20% longer compared with white men who received the same treatment. These findings will be presented at the upcoming 2019 Genitourinary Cancers Symposium in San Francisco, California.

Pembrolizumab Plus Axitinib Extended Overall Survival and Progress-Free Survival Versus Current Standard Treatment for Advanced Kidney Cancer

San Francisco, CA USA (UroToday.com) -- Results from the randomized, phase III KEYNOTE-426 clinical trial show that first-line therapy with a combination of the PD-1 targeted immunotherapy pembrolizumab (Keytruda) and the VEGF-targeted tyrosine kinase inhibitor axitinib (Inlyta) extended both overall survival and progression-free survival for patients with clear-cell metastatic renal cell carcinoma (mRCC), compared with the current standard of care, sunitinib (Sutent). Findings from this international study will be presented at the upcoming 2019 Genitourinary Cancers Symposium in San Francisco, CA.

Blue Earth Diagnostics Announces Axumin® (Fluciclovine F 18) LOCATE Study Presentation at Upcoming ASCO 2019 Genitourinary Cancers Symposium on Impact on Clinical Management of Recurrent Prostate Cancer

San Francisco, CA USA (UroToday.com) -- Blue Earth Diagnostics, a molecular imaging diagnostics company, today announced the upcoming presentation of additional analyses from the LOCATE clinical trial (NCT02680041). The LOCATE trial is a prospective, U.S., multicenter, open-label study investigating the impact of 18F fluciclovine PET/CT imaging on patient management of biochemically recurrent prostate cancer after initial prostate cancer treatment and negative or equivocal findings on standard-of-care imaging. The presentation will be made at the ASCO 2019 Genitourinary Cancers Symposium (ASCO GU), from February 14-16, 2019 in San Francisco, Ca. Details of the presentation to be given by Blue Earth Diagnostics collaborators is listed below.

ASCO GU 2019 Press Releases

Free Daily and Weekly newsletters offered by content of interest

Login